Paris-based company Quinten announces a €14 million fundraiser on 20 September. The roundtable was led by the equity growth investment fund Techlife Capital and Mutuelle d’Assurance du corps de santé français (MACSF).
Decision support tools
Quinten, founded in 2008 by Alexandre Templier, Guillaume Bourdon and Marie Alaoui, bills itself as a “data science and artificial intelligence company”. It offers decision support tools through the use of data, mainly in the field of healthcare. It is also present in banking/insurance. It is intended for pharmaceutical laboratories, medical device manufacturers and medical institutions in France, Europe and other countries.
With this new fundraising, the company wants to roll out two new software. The first, Quinten Health, is a real disease modeling reference software that allows pharmaceutical companies to support the clinical development and launch of their products. The goal is to reduce the time and cost of drug development.
Promoting the correct use of medicines
The second software was developed in partnership with the Hospital Center (CH) of Valenciennes, the University Hospital Center (CHU) of Montpellier, and with the support of the accelerating technology transfer company (SATT) axLR. PhamaIA allows hospital pharmacists to make analysis more reliable and faster, monitor medical prescriptions and identify situations with a high risk of side effects in real time. Purpose: to promote the correct use of the drug.
Since its inception, Quinten has completed nearly 350 projects with 50 organizations in many fields such as oncology, rare diseases, endocrinology, neurology, immunology, infectious diseases, and gastroenterology. In 2017, he partnered with Sanofi to improve real-world data.